-

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Scientific™ KingFisher™ PlasmidPro prepares high purity plasmid DNA in approximately 75 minutes, half the traditional process time and without the need for centrifugation

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ KingFisher™ PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention. This is the latest addition to the Thermo Scientific KingFisher instrument portfolio which offers a wide range of plasmid DNA extraction products to help drive efficiency and consistency.

Globally, there are approximately 1,700 clinical trials for cell and gene therapies.1 In recent years, plasmids have been instrumental in the development of cell and gene therapies, monoclonal antibody therapies and mRNA therapies and vaccines. Plasmids are commonly used in a variety of molecular biology applications, including transfection, protein expression, gene therapy, DNA sequencing, and vaccine development. They are a critical laboratory tool that can act as a carrier to deliver desired genes or DNA fragments into target cells.

“With the rapidly growing demand for plasmid DNA purification for emerging therapies, we are proud to accelerate the purification process with a ‘press and go’ solution,” said Amy Butler, president, biosciences, Thermo Fisher Scientific. “By fully automating a critical step in plasmid DNA manufacturing, the PlasmidPro DNA purification system can give time back to our customers to focus on their research and bringing life-saving therapies and vaccines to patients.”

The PlasmidPro purification system requires no set-up, centrifugation or pipetting and completely automates the purification process from culture to plasmid. The product uses a self-contained cartridge pre-filled with all necessary reagents to perform the purification, eliminating the need for additional instrumentation and plastics while minimizing set-up time and contamination risks. Using 100-150 mL of fresh overnight culture, the system is capable of producing up to 1.5 mg DNA yield.

For more information on PlasmidPro, please visit thermofisher.com/plasmidpro.

*For research use only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

1 https://alliancerm.org/wp-content/uploads/2024/05/Trials_Final_Q1_2024.pdf

Contacts

Media Contact Information:
Name: Kristin Blake
Phone: 760-637-1166
E-mail: kristin.blake@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Name: Kristin Blake
Phone: 760-637-1166
E-mail: kristin.blake@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care....

Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibco™ Bacto™ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli). As demand for plasmid DNA continues to surge to support expanding gene therapy and mRNA vaccin...

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...
Back to Newsroom